Africa CDC plans to present evidence to World Health Organization vaccine advisers in support of testing whether Merck's licensed Ebola vaccine, Ervebo, offers at least partial protection against the Bundibugyo virus driving the outbreak in the Democratic Republic of the Congo, Bloomberg reported at the end of July.
The move matters because it addresses the central gap in the response. There is no licensed vaccine for Bundibugyo ebolavirus, and the outbreak has become the largest ever recorded in the DRC, with WHO reporting 3,605 confirmed cases and 1,587 deaths as of July 30.
